No description available.

No description available.

Introduction: Les mutations du gène RAS sont présentes dans plusieurs types de cancers et ont une influence sur la réponse à la chimiothérapie. Excision repair cross- complementation group 1 (ERCC1) est un gène impliqué dans la réparation de l’acide désoxyribonucléique (ADN), et son polymorphisme au codon 118 est également associé à la réponse au traitement. Le peu d’études pronostiques portant sur ces deux gènes dans les cancers oto-rhino-laryngologiques (ORL) ne permet de tirer des conclusions claires. Objectifs: Déterminer l’influence des mutations de K-RAS codons 12 et 13 et du polymorphisme de ERCC1 codon 118 dans le traitement des cancers épidermoïdes avancés tête et cou traités par chimioradiothérapie concomitante à base de sels de platine. Méthode: Extraction de l’ADN provenant de spécimens de biopsie de patients traités par chimioradiothérapie concomitante pour des cancers avancés tête et cou, et ayant un suivi prospectif d’au moins deux ans. Identification des mutations de K-RAS codons 12 et 13 et du polymorphisme de ERCC1 au codon 118 dans les spécimens et corrélation de ces marqueurs avec la réponse au traitement. Résultats: Les mutations de K-RAS codon 12 sont associées à un moins bon contrôle loco-régional par rapport aux tumeurs ne démontrant pas la mutation (32% vs 83% p=0.03), sans affecter pour autant la survie globale. Aucune mutation de K-RAS codon 13 n’a été identifiée. Les différents polymorphismes de ERCC1 n’ont pas eu d’impact sur la réponse au traitement. Conclusion: Les mutations de K-RAS codons 12 et 13 et le polymorphisme de ERCC1 au codon 118 ne semblent pas mettre en évidence les patients qui bénéficieraient d’une autre modalité thérapeutique. / Background: RAS gene mutations have been shown to occur in certain malignancies and have an impact treatment response and overall prognosis. Excision repair cross- complementation group 1 (ERCC1) is a gene implicated in deoxyribonucleic acid (DNA) repair, whose polymorphism at codon 118 has been linked to treatment response. Studies of these two genes in head and neck oncology literature have shown inconsistent results. Objectives: Determine the influence of K-RAS mutations (codons 12 and 13) and the polymorphism of ERCC1 codon 118 in patients with locally advanced head and neck cancer treated with concomitant platinum-based chemoradiation therapy. Methods: DNA extraction from paraffin-embedded biopsy specimens of patients with advanced head and neck squamous cell carcinoma treated with concomitant chemoradiation and followed prospectively for at least two years. Identification of K- RAS mutations (codons 12 and 13) and ERCC1 codon 118 polymorphism in the extracted DNA. Correlation of these markers with treatment response. Results: K-RAS codon 12 mutations were associated with a worse locoregional control than tumors without any mutations (32% vs 83% p=0.03); however, mutational status did not influence overall survival. No K-RAS codon 13 mutation was identified in our specimens. The different ERCC1 polymorphisms did not have an impact on treatment response. Conclusion: K-RAS mutational status (codon 12 and 13) and ERCC1 codon 118 polymorphism does not seem to discriminate between patients for whom another treatment option should be sought in patients with locally advanced head and neck squamous cell carcinoma.

Le virus du papillome humain (HPV) est l’infection sexuellement transmise la plus fréquente au monde. Plusieurs études ont établi son implication dans l’étiologie de pratiquement tous les cancers du col de l’utérus, une maladie qui constitue un problème de santé majeur dans les pays pauvres. Le HPV est également responsable de 90% des cancers de l’anus, 40-50% des cancers du pénis, de la vulve et du vagin, et 30% des cancers de la tête et du cou. L’objectif général de cette thèse est de combler les lacunes relatives aux connaissances sur la distribution génotypique du HPV dans les lésions néoplasiques cervicales utérines et de la tête et du cou, plus particulièrement en Afrique. Les objectifs spécifiques sont les suivants: 1) analyser la distribution génotypique du HPV dans les cancers du col de l’utérus et faire une analyse comparative de cette distribution dans cinq pays africains en fonction de la prévalence du VIH; 2) évaluer la présence du HPV dans les cancers de la tête et du cou au Sénégal; 3) faire une revue de la littérature et une méta-analyse sur la distribution du HPV dans les cancers de la tête et du cou dans toutes les régions du monde. Pour le premier et le second objectifs, qui découlent d’un large projet international coordonné par l’Institut Catalan d’Oncologie pour l’Organisation Mondiale de la Santé (OMS), une étude transversale multicentrique a été menée au Mali et au Sénégal pour collecter des blocs de paraffine de patientes diagnostiquées entre 2001 et 2010 du cancer invasif du col et des cancers de la tête et du cou. Pour le troisième objectif, une revue exhaustive de la littérature a permis d’identifier tous les articles qui ont été publiés sur les cancers de la tête et du cou dans tous les pays du monde et d’effectuer une méta-analyse sur la prévalence de l’ADN du HPV selon le site du cancer et la région géographique. Notre analyse montre que les principaux types de HPV ciblés dans les vaccins prophylactiques (HPV16/18) représentent la majorité des types de HPV détectés dans le cancer invasif du col de l’utérus en Afrique subsaharienne. Par contre, le HPV45 vient au second rang dans certains pays d’Afrique, dont le Mali et le Sénégal. Nos données suggèrent également que le VIH aurait un rôle dans la contribution relative du HPV18 et HPV45 dans le développement du cancer du col de l’utérus. Au Sénégal, notre étude montre que la prévalence du HPV dans les cancers de la tête et du cou est très faible et ne semble pas jouer un rôle important dans l’oncogenèse. Finalement, la méta-analyse a mesuré la prévalence des HPV dans les cancers de la cavité orale, de l’oropharynx, du larynx et de l’hypopharynx, et confirme l’importante contribution relative du HPV16 dans ces cancers. Globalement, cette thèse permet de mieux comprendre l’impact potentiel des vaccins prophylactiques sur l’incidence des cancers associés au HPV. / Human papillomavirus (HPV) infection is the most common sexually transmitted infection worldwide. Several studies have shown its involvement in the etiology of virtually all cancers of the cervix, which is a major health problem in poor countries. HPV is also responsible for 90% of anal cancers, 40-50% of penile, vulvar and vaginal cancers, and 30% of head and neck cancers. The overall objective of this thesis is to fill the gaps in knowledge on the genotype distribution of HPV in anogenital and head and neck neoplasia, especially in sub-Saharan Africa. The specific objectives are to: 1) analyze HPV genotype distribution in cervical cancer and compare this distribution in five African countries according to HIV prevalence; 2) evaluate the presence of HPV in cancers of the head and neck in Senegal; 3) review the literature on the distribution of HPV in cancers of the head and neck in all regions of the world and perform a meta-analysis. For the first and second objectives, which were derived from a larger international project coordinated by the Catalan Institute of Oncology for the World Health Organization (WHO), a cross-sectional multicentric study was conducted to collect paraffin-embedded blocks of invasive cervical cancer and head and neck cancer diagnosed between 2001 and 2010 in Mali and Senegal. For the third objective, a comprehensive search of the literature was conducted to identify all articles published to date on head and neck cancer. A meta-analysis was performed to estimate the prevalence of HPV DNA according to cancer site and geographical region. Our analysis shows that the main HPV types targeted in the prophylactic vaccines (HPV16/18) accounted for the majority of the HPV types found in invasive cervical cancer in sub-Saharan Africa. Our data also suggests that HIV may play a role in the contribution of HPV18 and HPV45 to the development of cervical cancer. However, HPV45 ranks second in many African countries, notably in Mali and Senegal. In Senegal, our study shows that HPV DNA prevalence in head and neck cancer is very low and is not importantly involved in the oncogenesis. Finally, the meta-analysis measured the prevalence of HPV in cancers of the oral cavity, oropharynx, larynx and hypopharynx, and confirmed the significant relative contribution of HPV16 in these cancers. Overall, this thesis contributes to a better understanding of the potential impact of HPV prophylactic vaccines on the incidence of HPV-associated cancers.

Diss. Stockholm: Handelshögsk., 2002.

Made available in DSpace on 2014-06-11T19:32:14Z (GMT). No. of bitstreams: 0 Previous issue date: 2007-07-24Bitstream added on 2014-06-13T20:43:03Z : No. of bitstreams: 1 colombo_j_dr_sjrp.pdf: 949474 bytes, checksum: 856a4b47ea1a9aa6adebae3e2e97b6a0 (MD5) / Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) / Os tumores de cabeça e pescoço ocupam, mundialmente, a quinta posição na lista das neoplasias mais freqüentes. O tipo histológico predominante é o carcinoma de células escamosas, que acomete a cavidade oral, a orofaringe, a hipofaringe e a laringe. O tumor de laringe é um dos tipos mais comuns, correspondendo a 25% dos casos, com alto índice de mortalidade e prognóstico reservado. O principal fator etiológico para o seu desenvolvimento é o consumo combinado de álcool e fumo. O desenvolvimento do câncer de cabeça e pescoço é um processo multipasso acompanhado por mudanças genéticas e epigenéticas. Recentemente, estudos envolvendo a tecnologia microarray têm identificado genes específicos, cuja expressão está alterada em câncer de cabeça e pescoço quando comparado ao tecido normal. No entanto, a maioria dos estudos são realizados usando tumores de diferentes sítios. Neste estudo, foi analisado somente amostras de carcinoma de laringe para minimizar as diferenças genéticas. Dessa forma, os objetivos do presente projeto foram identificar e validar possíveis biomarcadores moleculares envolvidos na carcinogênese de laringe. Para tanto, foi construído um cDNA microarray com 340 genes previamente identificados pelo Head and Neck Annotation Consortium. A expressão desses genes foi analisada em 8 amostras de tecido tumoral e em 4 amostras de tecido histologicamente normal de laringe pela técnica de microarray. Foram identificados 35 genes diferencialmente expressos (SNR ½1.0½, p-value 0.001), os quais estão envolvidos em diversos processos celulares como adesão celular, apoptose, ciclo celular, inibição de proteases, metabolismo, proteólise, reparo de DNA, regulação da transcrição e transdução de sinal. A robustez da assinatura dos 35 genes diferencialmente expressos foi confirmada em um conjunto adicional de 5 amostras tumorais e 6 amostras... / Head and neck squamous cell carcinoma (HNSCC) is the fifth most common cancer world-wide. More than 90% of this cancer type has a squamous origin and common sites include oral cavity, oropharynx, hypopharynx and larynx Laryngeal squamous cell carcinoma is very common in head and neck cancer, corresponding to 25% of cases, with high mortality rates and poor prognosis. Tobacco use and/or alcohol consumption are the two principal risk factors involved in development of HNSCC. The development of head and neck cancer is a multistep process accompanied by genetic and epigenetic changes. In recent years, studies involving microarrays have identified specific genes whose expression has changed in head and neck cancer compared with normal tissue. However, most microarray studies are performed using tumors from different sites in head and neck. In our study, we analyzed only larynx carcinoma samples to minimize the genetic differences. Thus, the purpose of this work was to identify and to validater molecular biomarkers involved in larynx carcinogenesis. Therefore, we constructed a cDNA microarray containing 340 genes previously identified by Head and Neck Annotation Consortium. Expression analysis was applied to 8 larynx tumor samples and 4 larynx normal samples. We identified 35 differentially expressed genes between tumor and non-tumor adjacent tissue of larynx (SNR ½1.0½, p-value 0.001). Genes detected were involved in processes as apoptosis, cell adhesion, cell cycle, DNA repair, metabolism, protease inhibition, proteolysis, signal transduction and transcription regulation. The robustness of the 35-gene signature was confirmed using data from an additional set of 5 larynx tumor samples and 6 adjacent non-tumor larynx tissues. For real time RT-PCR validation we selected fourteen genes, of which 10 (ADCY6, AES, AL2SCR3, CRR9, CSTB, DUSP1, MAP3K5, PLAT, UBL1 and ZNF706) were validated... (Complete abstract click electronic access below)

The clinical introduction of proton therapy requires an extensive analysis of its benefits compared to conventional radiotherapy and a detailed analysis of possible uncertainties which might have serious consequences for patient treatment. In the first part of the presented thesis, the expected toxicities were evaluated for a treatment of head and neck cancer patients using a biologically adapted dose escalation schedule with photon and proton therapy. The feasibility of the dose escalation schedule could be demonstrated for both photon and proton therapy, since only a small increase in toxicity risk occurred for most toxicities. However, the expected toxicity risks were in most cases smaller with proton therapy. Furthermore, a higher benefit was found for patients with primary tumour locations in the upper head and neck area, who thus might be preferably referred to proton therapy. In the second part of this thesis, an extensive analysis of the impact of tumour motion in lung cancer treatment with active-scanning proton therapy was conducted. It could be shown, that dose degradations were small for tumour motion amplitudes below 5 mm. Parameters like the target volume concept, the optimisation approach, changes in the motion pattern and application sequence times had additional impact on the dose degradation. However, their magnitude was patient specific. Since not all parameters can be assessed before treatment, e.g. the motion pattern during treatment, prospective estimations should be supplemented by retrospective analyses. / Die Einführung der Protonentherapie in die klinische Praxis erfordert umfassende Analysen ihrer Vor- und Nachteile im Vergleich zur konventionellen Photonentherapie sowie detaillierte Untersuchungen der Auswirkungen von Unsicherheiten in der Therapieapplikation. Im ersten Teil der vorliegenden Arbeit wurden die zu erwartenden Nebenwirkungen bei der Behandlung von Patienten mit Kopf-Hals-Tumoren mit einem biologisch-adaptierten Fraktionierungsschema inklusive Dosiseskalation mit Photonen- und Protonentherapie evaluiert. Dabei konnte gezeigt werden, dass die Dosiseskalation sowohl mit Photonen- als auch Protonentherapie angewandt werden kann, da die Wahrscheinlichkeit für das Auftreten von Nebenwirkungen in den meisten Fällen kaum erhöht wurde. Weiterhin wurden die Nebenwirkungswahrscheinlichkeiten mit der Protonentherapie im Vergleich zur Photonentherapie reduziert. Dies war vor allem für Patienten mit Tumoren im oberen Kopf-Hals-Bereich der Fall. Diese könnten daher bevorzugt zur Protonentherapie überwiesen werden. Darüber hinaus wurde im zweiten Teil der Arbeit eine umfassende Analyse des Einflusses der Tumorbewegung auf die Dosisverteilung bei Behandlung von Lungentumoren mit aktiver Protonenstrahlformierung durchgeführt. Dabei zeigte sich, dass Dosisdegradierungen bei Bewegungsamplituden unter 5mm gering sind. Parameter wie das Zielvolumenkonzept, Veränderungen des Bewegungsmusters oder der Applikationszeiten nehmen zusätzlich Einfluss auf die Dosisdegradierung, allerdings in unterschiedlichem Maß für individuelle Patienten. Da nicht alle Parameter vor Behandlung bekannt sein können, sollten prospektive Dosisabschätzungen durch retrospektive Analysen ergänzt werden.

No description available.

Les études d'association à grande échelle consistent à étudier la corrélation de plusieurs millions de polymorphismes nucléotidiques avec un risque de cancer chez des milliers d'individus, sans avoir besoin de connaissances préalables sur la fonction biologique de ces variants. Ces études ont été utiles pour établir des hypothèses étiologiques et comprendre l'architecture génétique sous-jacente de plusieurs maladies humaines. Cependant, la plupart des facteurs héréditaires de ces maladies restent inexpliqués. Une partie de cette variation pourrait venir de variants rares qui ne sont pas ciblés par les puces de génotypage actuelles ou encore de variants avec un effet plus modéré voire faible pour lesquels une détection par les études d'association actuelles n'est pas envisageable. Dans ce contexte et comme illustré dans cette thèse, les récentes études d'association peuvent maintenant servir de point de départ pour de nouvelles découvertes, en mettant en place des stratégies innovantes pour étudier à la fois les variants rares et les maladies rares. Nous avons plus particulièrement exploré ces techniques dans le cadre du cancer du poumon, des voies aérodigestives et du lymphome de Hodgkins. L'utilisation de la bioinformatique pour combiner les résultats des études avec d'autres sources d'information, l'intégration de différents types de données génomiques ainsi que l'investigation de la relation entre altérations germinales et somatiques représentent les principales opportunités poursuivies dans ce travail de thèse / Genome-wide association (GWA) studies consist in testing up to one million (or more) single nucleotide polymorphisms (SNPs) for their association with cancer risk in thousands of individuals, without requiring any prior knowledge on the functional significance of these variants. These studies have been valuable for establishing etiological hypotheses and understanding the underlying genetic architecture of human diseases. However, most of the heritable factors of these traits remain unexplained. Part of this variation may come from rarer variants that are not targeted by current genotyping arrays or variants with moderate to low effects for which detection by current GWA studies is impractical. In this context and as illustrated in this thesis, GWA studies can now serve as starting points towards further discoveries, looking for new strategies to study both rarer variants and rarer diseases. We have specifically explored these approaches in the context of lung cancer, head and neck cancer and Hodgkin's lymphoma. The use of bioinformatics to combine recent GWA study results with other sources of information, the integration of different types of genomic data as well as the investigation of the interrelationship between germline and somatic alterations represent the main opportunities pursued in this thesis work

O tratamento radioterápico é considerado como uma das modalidades terapêuticas padrão para os cânceres de cabeça e pescoço, cujo objetivo é controlar a evolução do tumor com o menor dano possível aos tecidos e órgãos normais adjacentes, porém, apesar de apresentar a vantagem de preservar a estrutura dos tecidos, pode acarretar reações adversas que se manifestam na cavidade oral, e também efeitos colaterais físicos generalizados, sendo a fadiga o mais comum. Objetivo: avaliar a efetividade da Prática Integrativa e Complementar - Relaxamento com Visualização Guiada, sobre a redução do sintoma de fadiga e melhora da Qualidade de Vida Relacionada à Saúde, durante o tratamento radioterápico. Método: estudo quantitativo, quase-experimental, de corte longitudinal e prospectivo, com a participação de 102 pacientes em início de tratamento radioterápico, com a alocação intencional em dois grupos, o de Intervenção (n=42) e o de Comparação (n=60). Apenas os participantes do Grupo Intervenção realizaram a prática de relaxamento com visualização guiada durante o tratamento radioterápico, porém, todos os participantes responderam aos questionários de avaliação. Foram utilizados os questionários de Qualidade de Vida Relacionada à Saúde (FACT H&N) e a Escala de Fadiga de Piper Revisada. A prática de relaxamento com visualização guiada foi aplicada pela pesquisadora do estudo, por meio de uma gravação de áudio contendo comandos verbais, os quais guiavam o paciente para a realização da prática. Para avaliar o efeito da intervenção entre os grupos intervenção e de controle, foi utilizada a técnica de regressão logística multinomial, estimando razões de chance (odds ratios) por pontos e respectivos erros-padrão (Ep). Resultados: na etapa descritiva dos dados sociodemográficos e clínicos, evidenciou-se a predominância do sexo masculino, faixa etária entre 41 e 60 anos, baixo nível de escolaridade, aposentados, católicos, em uso regular de álcool e tabaco, câncer de orofaringe, em estádio IV. Foram evidenciadas diferenças estatisticamente significativas entre os grupos em relação às variáveis procedência, estado civil e \"tipo de cirurgia\" e os valores-p foram, respectivamente, p=0,000, p= 0,002 e p=0,027. Na etapa analítica evidenciou-se que o relaxamento com visualização guiada mostrou-se efetivo em especial para os domínios global, comportamental e sensorial na segunda aplicação (T2), e afetivo e sensorial na terceira aplicação (T3), levando à redução do sintoma de fadiga, e quanto à Qualidade de Vida Relacionada à Saúde não houve diferença estatisticamente significativa entre os grupos. Conclusão: os resultados demonstraram que o relaxamento com visualização guiada não teve efeito na melhora da Qualidade de Vida Relacionada à Saúde durante o tratamento radioterápico nos pacientes com câncer de cabeça e pescoço, mas reduziu os níveis de fadiga. Trata-se de uma prática de baixo custo, a qual mostrou-se efetiva na redução do sintoma de fadiga, portanto, seu uso deve ser divulgado na prática dos cuidados aos pacientes oncológicos / Radiation therapy is considered to be one of the standard therapeutic modalities for head and neck cancers in order to control tumor evolution with the lowest possible damage to adjacent normal tissues and organs. Although it has the advantage of preserving the structure of tissues, it can lead to adverse reactions occurring in the oral cavity, as well as generalized physical side effects, being fatigue the most common of them. Objective: to evaluate the effectiveness of an Integrative and Complementary Practice - Relaxation with Guided Imagery, on the reduction of fatigue symptom and improvement of Health-Related Quality of Life, during the radiotherapy treatment. METHODS: A quantitative, quasi-experimental, longitudinal and prospective study was carried out with the participation of 102 patients at the beginning of radiotherapy, intentionally allocated in two groups: Intervention (n=42) and Comparison (n = 60). While only the participants of the Intervention Group performed the relaxation practice with guided imagery during the radiotherapy treatment, all the participants answered the evaluation questionnaires. The HealthRelated Quality of Life questionnaires (FACT-H&N) and the revised Piper Fatigue Scale were used. The practice of relaxation with guided imagery was applied by the researcher of the study, through an audio recording containing verbal commands, which guided the patient to perform the practice. To evaluate the effects of the intervention comparing the intervention and control groups, it was used multinomial logistic regression technique in order to estimate odds ratios by points and their respective standard errors (SE). Results: the descriptive stage found in the sociodemographic and clinical data, the prevalence of males, age between 41 and 60 years old, low level of schooling, retirees, Catholics, regular use of alcohol and tobacco, as well as oropharynx cancer in stage IV. There were statistically significant differences between the groups related to the variables place of residence, marital status and \"type of surgery\", while the p-values were respectively, p=0.000, p=0.002 and p = 0.027. In the analytical stage, it was observed that the relaxation with guided imagery was effective for the global, behavioral and sensorial domains in the second application (T2), as well as for the affective and sensorial domains in the third application (T3), leading to the reduction of the fatigue symptoms, while there was no statistically significant difference between the groups related to Health-Related Quality of Life. Conclusion: The results showed that while guided imagery relaxation had no effect on the improvement of the Health-Related Quality of Life during the radiotherapy treatment in patients with head and neck cancer, it still reduced fatigue levels. It is a low-cost practice, which has proved effective in reducing the fatigue symptoms, so its use must be disseminated in caring practices directed to cancer patients